Federal regulators alleged Tuesday that an Illinois-based company bought the only two medicines approved to treat premature babies born with a potentially life-threatening congenital heart defect, and then increased prices nearly 1,300 percent.
The Federal Trade Commission said in a civil lawsuit that Ovation Pharmaceuticals Inc., illegally maintained a monopoly in drug treatments for the heart defect. The commission seeks to prevent Ovation from maintaining simultaneous interest in the two drugs — NeoProfen and Indocin. Also, it seeks forfeiture of all unlawfully obtained profits.
The commission said Ovation purchased the rights to Indocin in August 2005 and then acquired the rights to NeoProfen five months later. It set the price for the two medicines at about $500. Before the second acquisition, Indocin was priced at $36.
An estimated 30,000 babies are treated with the drugs each year.
"Ovation's profiteering on the backs of critically ill premature babies is not only immoral, it is illegal," said FTC Commissioner Jon Leibowitz in a statement issued separately from the lawsuit.
Ovation Pharmaceuticals Inc., based in Deerfield, Ill., rejected the commission's allegations. It said NeoProfen is superior to Indocin, and is not interchangeable for most premature infants with the heart defect.
Subscribe to:
Post Comments (Atom)
0 comments:
Post a Comment